Mercyone Waterloo Medical Center
- Type
- Teaching hospital
- Where
- Saginaw, MI
- Medicare CCN
- 160067
- Received
- $909,918 in 88 records, 2022 ($11,438 general, $898,479 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2022 | General payment | 23 | $11,438 |
| 2022 | Research payment | 65 | $898,479 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Eli Lilly and Company | 5 | $805,134 | 2022 |
| MicroPort Orthopedics Inc | 3 | $54,619 | 2022 |
| Esperion Therapeutics, Inc. | 55 | $26,226 | 2022 |
| Celgene Corporation | 1 | $10,500 | 2022 |
| Olympus America Inc. | 2 | $3,933 | 2022 |
| Siemens Medical Solutions USA, Inc. | 2 | $3,683 | 2022 |
| Linvatec Corporation | 1 | $2,225 | 2022 |
| Helsinn Healthcare SA | 1 | $2,000 | 2022 |
| Foundation Medicine, Inc. | 1 | $770 | 2022 |
| Barco, Inc. | 1 | $514 | 2022 |
| Merge Healthcare Incorporated | 16 | $312 | 2022 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 65 | $898,479 |
| Debt forgiveness | 4 | $7,617 |
| Long term medical supply or device loan | 2 | $2,739 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 1 | $770 |
| Food and Beverage | 16 | $312 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | Linvatec Corporation | $2,225 | Long term medical supply or device loan | In-kind items and services | AIRSEAL Device, GENERAL SURGERY | 2022 | |
| 2022-12-31 | Siemens Medical Solutions USA, Inc. | $161 | Debt forgiveness | In-kind items and services | 2022 | ||
| 2022-12-28 | Foundation Medicine, Inc. | $770 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FOUNDATIONONE CDX Device, ONCOLOGY | 2022 | |
| 2022-12-02 | Barco, Inc. | $514 | Long term medical supply or device loan | In-kind items and services | MDRC-2222 BL Device | 2022 | |
| 2022-10-25 | Merge Healthcare Incorporated | $70 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-10-05 | MicroPort Orthopedics Inc | $10,731 | Research payment | Cash or cash equivalent | MPO Medial Pivot Knee Device, Orthopedic Product | PMCF Study for Evolution Biofoam Tibia and Evolution CS/CR Porous Femur with Cruciate Sacrificing Insert | 2022 |
| 2022-09-13 | Celgene Corporation | $10,500 | Research payment | Cash or cash equivalent | Connect MM- The Multiple Myeloma Disease Registry | 2022 | |
| 2022-09-12 | Merge Healthcare Incorporated | $12 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-09-12 | Merge Healthcare Incorporated | $12 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-09-12 | Merge Healthcare Incorporated | $12 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-09-12 | Merge Healthcare Incorporated | $12 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-09-12 | Merge Healthcare Incorporated | $12 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-09-12 | Merge Healthcare Incorporated | $12 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-08-28 | Eli Lilly and Company | $1,199 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2022 | |
| 2022-08-19 | Esperion Therapeutics, Inc. | $1,261 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-19 | Esperion Therapeutics, Inc. | $1,261 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-19 | Esperion Therapeutics, Inc. | $226 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-19 | Esperion Therapeutics, Inc. | $226 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-19 | Esperion Therapeutics, Inc. | $226 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-19 | Esperion Therapeutics, Inc. | $226 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-19 | Esperion Therapeutics, Inc. | $226 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-19 | Esperion Therapeutics, Inc. | $226 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-19 | Esperion Therapeutics, Inc. | $226 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-19 | Esperion Therapeutics, Inc. | $226 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-19 | Esperion Therapeutics, Inc. | $226 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-19 | Esperion Therapeutics, Inc. | $226 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-11 | Eli Lilly and Company | $5,628 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIM | 2022 | |
| 2022-08-05 | Esperion Therapeutics, Inc. | $105 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | $105 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | $105 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | $105 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | $105 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | $82 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | $82 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | $82 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | $82 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | $82 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | $82 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | $82 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | $82 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | $50 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | $50 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | $50 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | $50 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-28 | Siemens Medical Solutions USA, Inc. | $3,522 | Debt forgiveness | Cash or cash equivalent | 2022 | ||
| 2022-07-21 | Esperion Therapeutics, Inc. | $1,261 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $1,261 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $1,261 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $1,261 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $1,261 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $1,261 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $1,261 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $1,261 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $226 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $226 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-12 | Merge Healthcare Incorporated | $21 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-07-12 | Merge Healthcare Incorporated | $21 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-07-08 | Esperion Therapeutics, Inc. | $1,261 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-08 | Esperion Therapeutics, Inc. | $1,261 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-08 | Esperion Therapeutics, Inc. | $586 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-08 | Esperion Therapeutics, Inc. | $586 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-08 | Esperion Therapeutics, Inc. | $586 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-08 | Esperion Therapeutics, Inc. | $586 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-08 | Esperion Therapeutics, Inc. | $586 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-08 | Esperion Therapeutics, Inc. | $338 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-08 | Esperion Therapeutics, Inc. | $338 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-08 | Esperion Therapeutics, Inc. | $226 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-08 | Esperion Therapeutics, Inc. | $226 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-08 | Esperion Therapeutics, Inc. | $226 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-08 | Esperion Therapeutics, Inc. | $226 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-10 | Merge Healthcare Incorporated | $16 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-06-10 | Merge Healthcare Incorporated | $16 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-06-10 | Merge Healthcare Incorporated | $16 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-06-06 | MicroPort Orthopedics Inc | $13,773 | Research payment | Cash or cash equivalent | MPO Medial Pivot Knee Device, Orthopedic Product | PMCF Study for Evolution Biofoam Tibia and Evolution CS/CR Porous Femur with Cruciate Sacrificing Insert | 2022 |
| 2022-05-04 | MicroPort Orthopedics Inc | $30,114 | Research payment | Cash or cash equivalent | MPO Medial Pivot Knee Device, Orthopedic Product | PMCF Study for Evolution Biofoam Tibia and Evolution CS/CR Porous Femur with Cruciate Sacrificing Insert | 2022 |
| 2022-05-03 | Eli Lilly and Company | $315,458 | Research payment | Cash or cash equivalent | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2022 | |
| 2022-05-03 | Helsinn Healthcare SA | $2,000 | Research payment | Cash or cash equivalent | A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamore | 2022 | |
| 2022-04-25 | Esperion Therapeutics, Inc. | $1,800 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-04-25 | Esperion Therapeutics, Inc. | $586 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-04-25 | Esperion Therapeutics, Inc. | $105 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-04-21 | Merge Healthcare Incorporated | $19 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-04-21 | Merge Healthcare Incorporated | $19 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-04-21 | Merge Healthcare Incorporated | $19 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-04-21 | Merge Healthcare Incorporated | $19 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-03-31 | Olympus America Inc. | $2,258 | Debt forgiveness | In-kind items and services | DORNHOFFER INTERPOSITIONALPORP W TITANIUM CRADLE3 MM OVERALL LENGTH 2 MM FUNCT Device, Ear, Nose, Throat | 2022 | |
| 2022-03-31 | Olympus America Inc. | $1,675 | Debt forgiveness | In-kind items and services | Olympus Device, Urology Gynecology | 2022 | |
| 2022-02-08 | Eli Lilly and Company | $3,456 | Research payment | In-kind items and services | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2022 | |
| 2022-01-04 | Eli Lilly and Company | $479,393 | Research payment | Cash or cash equivalent | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2022 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Saginaw, MI, county Saginaw County, MI, state Michigan; placed by its city name.
| Measure | Place (city or town) Saginaw, MI | County Saginaw County, MI | State Michigan |
|---|---|---|---|
| Population B01003 | 43,536 | 188,665 | 10,077,761 |
| Population, 2020 census P1 | 44,202 | 190,124 | 10,077,331 |
| Median age B01002 | 35.5 | 41.2 | 40.2 |
| Under 18 B01001 | 25.6% | 21.3% | 21.2% |
| 65 and over B01001 | 14.9% | 20.4% | 18.6% |
| Households B11001 | 17,789 | 77,958 | 4,076,369 |
| Foreign born B05002 | 1.4% | 2.4% | 7.2% |
| Median household income B19013 | $38,579 | $60,622 | $72,875 |
| Median family income B19113 | $47,904 | $77,136 | $93,357 |
| Per capita income B19301 | $21,177 | $34,578 | $40,735 |
| Poverty rate B17001 | 34.0% | 18.2% | 13.2% |
| Unemployment rate B23025 | 10.1% | 6.4% | 5.7% |
| Civilian labor force B23025 | 18,729 | 87,598 | 5,018,449 |
| Mean commute (minutes) B08013 | 19.2 | 22.4 | 24.2 |
| Bachelor's degree or higher B15003 | 13.3% | 24.4% | 32.4% |
| Housing units B25001 | 21,063 | 86,208 | 4,622,236 |
| Owner-occupied B25003 | 60.0% | 74.1% | 73.2% |
| Renters B25003 | 40.0% | 25.9% | 26.8% |
| Median home value B25077 | $60,000 | $152,800 | $231,600 |
| Median gross rent B25064 | $922 | $947 | $1,129 |
| White, not Hispanic B03002 | 34.7% | 67.8% | 72.4% |
| Black B03002 | 44.3% | 18.1% | 13.1% |
| Hispanic or Latino B03002 | 15.9% | 9.2% | 5.9% |
| Asian B03002 | 0.2% | 1.2% | 3.4% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Saginaw, MI.
Comments